Comparative Study of the Quality of Life of Patients with Chemotherapy-Induced Ototoxicity Fitted with Hearing Aids Compared to Those Not Fitted

What this Trial Is About

Many patients receiving platinum-based chemotherapy experience hearing problems such as ototoxicity, tinnitus, and reduced hearing acuity, which can significantly affect quality of life and treatment adherence. This study aims to compare quality of life in patients suffering from chemotherapy-induced ototoxicity who are fitted with hearing aids versus those who continue with their usual care. The study is sponsored by the Institut de Cancérologie de Lorraine and addresses the lack of consensus on managing hearing side effects from platinum treatments. Participants will be randomly assigned to one of two groups: one group will continue their usual care without hearing aids, and the other group will receive standard treatment plus hearing aids. At baseline, all patients undergo clinical and audiometric examinations and complete a quality of life survey (SF36). Follow-up visits occur at one, three, and six months after fitting, including clinical and hearing assessments and repeated quality of life questionnaires. At the six-month visit, all participants complete a satisfaction questionnaire. Throughout the study, patients continue their platinum-based chemotherapy as recommended for their cancer. Researchers will measure quality of life, hearing ability, tinnitus symptoms, and patient compliance with wearing hearing aids over six months. Clinical examinations and audiometric or tinnitus tests are performed at each scheduled visit as part of standard care. The study monitors patient outcomes to evaluate the impact of hearing aids on life quality during chemotherapy treatment.

Comparative Study of the Quality of Life of Patients Suffering From OTOTOXICITY Due to Chemotherapy Based on Platinum Salts Fitted With a Hearing Aid Compared to Those Not Fitted.